• 1. Fe3O4@PANI: a magnetic polyaniline nanomaterial for highly efficient and handy enrichment of intact N-glycopeptides??
  Zhizhen Lai,Mo Zhang,Jinyu Zhou,Tianjing Chen,Dan Li,Xuejing Shen,Jia Liu,Jiang Zhou,Zhili Li Analyst, 2021,146, 4261-4267
• 2. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 3. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?
  Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
• 4. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 5. Distributed research: a new paradigm for undergraduate research and global problem solving?
  Bruce Parkinson Energy Environ. Sci., 2010,3, 509-511

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

(3R)-3-Amino-3-(2,3-difluorophenyl)propanoic acid (CAS No. 1228571-43-4): A Comprehensive Overview

(3R)-3-Amino-3-(2,3-difluorophenyl)propanoic acid (CAS No. 1228571-43-4) is a chiral amino acid derivative that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique structural features, including a 2,3-difluorophenyl substituent and an (R)-configured chiral center, which contribute to its potential therapeutic applications and biological activities.

The synthesis of (3R)-3-Amino-3-(2,3-difluorophenyl)propanoic acid has been extensively studied due to its importance in the development of novel drugs. One of the most common synthetic routes involves the asymmetric hydrogenation of a prochiral ketone or aldehyde followed by amination. Recent advancements in catalytic asymmetric hydrogenation have significantly improved the yield and enantiomeric purity of this compound, making it more accessible for large-scale production.

In terms of its biological properties, (3R)-3-Amino-3-(2,3-difluorophenyl)propanoic acid has shown promising activity in various pharmacological assays. Studies have demonstrated its potential as a modulator of G protein-coupled receptors (GPCRs), which are key targets for many therapeutic agents. Specifically, this compound has been found to exhibit agonistic or antagonistic effects on certain GPCRs, depending on the specific receptor subtype and cellular context.

One notable application of (3R)-3-Amino-3-(2,3-difluorophenyl)propanoic acid is in the treatment of neurological disorders. Research has shown that this compound can cross the blood-brain barrier and modulate neurotransmitter systems involved in conditions such as depression, anxiety, and neurodegenerative diseases. Preclinical studies have reported that it can improve cognitive function and reduce symptoms of depression in animal models.

Beyond its potential as a therapeutic agent, (3R)-3-Amino-3-(2,3-difluorophenyl)propanoic acid is also valuable as a building block for the synthesis of more complex molecules. Its unique structural features make it an excellent starting material for the development of peptidomimetics and other bioactive compounds. For example, it has been used to synthesize peptidomimetic inhibitors of proteases and kinases, which are important targets in cancer and inflammatory diseases.

The safety profile of (3R)-3-Amino-3-(2,3-difluorophenyl)propanoic acid is another critical aspect that has been investigated. Toxicological studies have shown that it exhibits low toxicity at therapeutic doses and does not cause significant adverse effects in preclinical models. However, further clinical trials are necessary to fully evaluate its safety and efficacy in human subjects.

In conclusion, (3R)-3-Amino-3-(2,3-difluorophenyl)propanoic acid (CAS No. 1228571-43-4) is a versatile compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique structural features and biological activities make it an attractive candidate for the development of novel therapeutic agents. Ongoing research continues to uncover new insights into its mechanisms of action and potential uses, further solidifying its importance in the field.

• 151911-32-9((S)-3-Amino-3-(2-fluoro-phenyl)-propionic acid)
• 1269963-27-0((3S)-3-Amino-3-(2,4,5-trifluorophenyl)propanoic acid)
• 682803-77-6(3-amino-3-(2,4,5-trifluorophenyl)propanoic acid)
• 682804-04-2(3-Amino-3-(2,3-difluorophenyl)propanoic acid)
• 151911-22-7((R)-3-Amino-3-(2-fluoro-phenyl)-propionic acid)
• 682804-49-5(3-Amino-3-pentafluorophenyl-propionic acid)
• 773122-52-4(3-amino-3-(2,5-difluorophenyl)propanoic acid)
• 1228561-26-9((3R)-3-Amino-3-(2,5-difluorophenyl)propanoic acid)
• 1228561-39-4((3S)-3-amino-3-(2,3-difluorophenyl)propanoic acid)
• 1228571-37-6((3S)-3-Amino-3-(2,5-difluorophenyl)propanoic Acid)